Kornitzer Capital Management Inc. KS Sells 4,025 Shares of IDEXX Laboratories, Inc. $IDXX

Kornitzer Capital Management Inc. KS trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 24.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,719 shares of the company’s stock after selling 4,025 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in IDEXX Laboratories were worth $7,147,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in IDXX. SHP Wealth Management acquired a new stake in IDEXX Laboratories during the fourth quarter worth approximately $26,000. Virtus Advisers LLC acquired a new position in IDEXX Laboratories in the third quarter valued at approximately $26,000. Park Place Capital Corp acquired a new position in IDEXX Laboratories in the fourth quarter valued at approximately $29,000. WealthCollab LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $30,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of IDEXX Laboratories during the 3rd quarter worth approximately $36,000. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on IDXX. Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 25th. UBS Group cut their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Finally, Citigroup began coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Seven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Stock Up 0.9%

NASDAQ:IDXX traded up $4.97 on Friday, hitting $563.57. The stock had a trading volume of 612,524 shares, compared to its average volume of 657,640. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 52 week low of $506.91 and a 52 week high of $769.98. The business’s fifty day moving average is $555.09 and its 200 day moving average is $604.44. The company has a market cap of $44.45 billion, a PE ratio of 41.50, a P/E/G ratio of 3.06 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the previous year, the company posted $2.91 earnings per share. The company’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities research analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.